Genetic and molecular changes in ovarian cancer

被引:79
作者
Hollis, Robert L. [1 ]
Gourley, Charlie [1 ]
机构
[1] Univ Edinburgh, Edinburgh Canc Res UK Ctr, MRC Inst Genet & Mol Med, Edinburgh EH4 2XR, Midlothian, Scotland
基金
英国医学研究理事会;
关键词
GRADE SEROUS CARCINOMA; CLEAR-CELL CARCINOMA; FALLOPIAN-TUBE; SOMATIC MUTATIONS; INTRAEPITHELIAL CARCINOMA; GERMLINE MUTATIONS; PROGNOSTIC-FACTOR; TUMOR-SUPPRESSOR; BRCA2; MUTATIONS; TP53;
D O I
10.20892/j.issn.2095-3941.2016.0024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Epithelial ovarian cancer represents the most lethal gynecological malignancy in the developed world, and can be divided into five main histological subtypes: high grade serous, endometrioid, clear cell, mucinous and low grade serous. These subtypes represent distinct disease entities, both clinically and at the molecular level. Molecular analysis has revealed significant genetic heterogeneity in ovarian cancer, particularly within the high grade serous subtype. As such, this subtype has been the focus of much research effort to date, revealing molecular subgroups at both the genomic and transcriptomic level that have clinical implications. However, stratification of ovarian cancer patients based on the underlying biology of their disease remains in its infancy. Here, we summarize the molecular changes that characterize the five main ovarian cancer subtypes, highlight potential opportunities for targeted therapeutic intervention and outline priorities for future research.
引用
收藏
页码:236 / 247
页数:12
相关论文
共 120 条
  • [1] Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
    Ahmed, Ashour Ahmed
    Etemadmoghadam, Dariush
    Temple, Jillian
    Lynch, Andy G.
    Riad, Mohamed
    Sharma, Raghwa
    Stewart, Colin
    Fereday, Sian
    Caldas, Carlos
    DeFazio, Anna
    Bowtell, David
    Brenton, James D.
    [J]. JOURNAL OF PATHOLOGY, 2010, 221 (01) : 49 - 56
  • [2] Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas
    Anglesio, Michael S.
    Kommoss, Stefan
    Tolcher, Mary C.
    Clarke, Blaise
    Galletta, Laura
    Porter, Henry
    Damaraju, Sambasivarao
    Fereday, Sian
    Winterhoff, Boris J.
    Kalloger, Steve E.
    Senz, Janine
    Yang, Winnie
    Steed, Helen
    Allo, Ghassan
    Ferguson, Sarah
    Shaw, Patricia
    Teoman, Attila
    Garcia, Joaquin J.
    Schoolmeester, John K.
    Bakkum-Gamez, Jamie
    Tinker, Anna V.
    Bowtell, David D.
    Huntsman, David G.
    Gilks, C. Blake
    McAlpine, Jessica N.
    [J]. JOURNAL OF PATHOLOGY, 2013, 229 (01) : 111 - 120
  • [3] [Anonymous], J NAT CANC I
  • [4] [Anonymous], 1993, Cancer
  • [5] Ovarian Endometrioid Adenocarcinoma: Incidence and Clinical Significance of the Morphologic and Immunohistochemical Markers of Mismatch Repair Protein Defects and Tumor Microsatellite Instability
    Aysal, Anil
    Karnezis, Anthony
    Medhi, Irum
    Grenert, James P.
    Zaloudek, Charles J.
    Rabban, Joseph T.
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2012, 36 (02) : 163 - 172
  • [6] Baldwin RL, 2000, CANCER RES, V60, P5329
  • [7] Mucinous But Not Clear Cell Histology Is Associated With Inferior Survival in Patients With Advanced Stage Ovarian Carcinoma Treated With Platinum-Paclitaxel Chemotherapy
    Bamias, Aristotle
    Psaltopoulou, Theodora
    Sotiropoulou, Maria
    Haidopoulos, Dimitrios
    Lianos, Evangelos
    Bournakis, Evangelos
    Papadimitriou, Christos
    Rodolakis, Alexandros
    Vlahos, George
    Dimopoulos, Meletius A.
    [J]. CANCER, 2010, 116 (06) : 1462 - 1468
  • [8] Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling
    Bashashati, Ali
    Ha, Gavin
    Tone, Alicia
    Ding, Jiarui
    Prentice, Leah M.
    Roth, Andrew
    Rosner, Jamie
    Shumansky, Karey
    Kalloger, Steve
    Senz, Janine
    Yang, Winnie
    McConechy, Melissa
    Melnyk, Nataliya
    Anglesio, Michael
    Luk, Margaret T. Y.
    Tse, Kane
    Zeng, Thomas
    Moore, Richard
    Zhao, Yongjun
    Marra, Marco A.
    Gilks, Blake
    Yip, Stephen
    Huntsman, David G.
    McAlpine, Jessica N.
    Shah, Sohrab P.
    [J]. JOURNAL OF PATHOLOGY, 2013, 231 (01) : 21 - 34
  • [9] Personalizing Therapy for Ovarian Cancer: BRCAness and Beyond
    Bast, Robert C., Jr.
    Mills, Gordon B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (22) : 3545 - 3548
  • [10] Integrated genomic analyses of ovarian carcinoma
    Bell, D.
    Berchuck, A.
    Birrer, M.
    Chien, J.
    Cramer, D. W.
    Dao, F.
    Dhir, R.
    DiSaia, P.
    Gabra, H.
    Glenn, P.
    Godwin, A. K.
    Gross, J.
    Hartmann, L.
    Huang, M.
    Huntsman, D. G.
    Iacocca, M.
    Imielinski, M.
    Kalloger, S.
    Karlan, B. Y.
    Levine, D. A.
    Mills, G. B.
    Morrison, C.
    Mutch, D.
    Olvera, N.
    Orsulic, S.
    Park, K.
    Petrelli, N.
    Rabeno, B.
    Rader, J. S.
    Sikic, B. I.
    Smith-McCune, K.
    Sood, A. K.
    Bowtell, D.
    Penny, R.
    Testa, J. R.
    Chang, K.
    Dinh, H. H.
    Drummond, J. A.
    Fowler, G.
    Gunaratne, P.
    Hawes, A. C.
    Kovar, C. L.
    Lewis, L. R.
    Morgan, M. B.
    Newsham, I. F.
    Santibanez, J.
    Reid, J. G.
    Trevino, L. R.
    Wu, Y. -Q.
    Wang, M.
    [J]. NATURE, 2011, 474 (7353) : 609 - 615